MedPath
HSA Approval

CON-Z-LIN TABLET

SIN05768P

CON-Z-LIN TABLET

CON-Z-LIN TABLET

April 22, 1991

CENTRAL CHEMICAL & ENTERPRISES PTE. LTD.

CENTRAL CHEMICAL & ENTERPRISES PTE. LTD.

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantCENTRAL CHEMICAL & ENTERPRISES PTE. LTD.
Licence HolderCENTRAL CHEMICAL & ENTERPRISES PTE. LTD.

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
General Sale List
HSA Singapore Classification

Formulation Information

TABLET, SUGAR COATED

ORAL

Medical Information

N02BA55

salicylamide, combinations excl. psycholeptics

Manufacturer Information

CENTRAL CHEMICAL & ENTERPRISES PTE. LTD.

SUNWARD PHARMACEUTICAL PRIVATE LIMITED

Active Ingredients

SALICYLAMIDE

250 mg

Salicylamide

CAFFEINE (ANHYDROUS)

15 mg

Caffeine

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

CON-Z-LIN TABLET - HSA Approval | MedPath